Repligen Corporation
41 Seyon Street Building 1
Suite 100
Waltham,
MA 02453
United States - Map
Phone: 781-250-0111
Fax: 781-250-0115
Web Site: http://www.repligen.com
| Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies. Repligen also licenses its patent covering the use of CTLA4-Ig, a regulator of the activity of the immune system, and receives royalties from Bristol-Myers Squibb based on their U.S. Sales of Orencia. The companys development stage products include RG1068, human secretin for improved MRI of the pancreas; RG2417, uridine for bipolar depression; HDAC inhibitors for Friedreichs ataxia; and RG-SMA for spinal muscular atrophy. The company sells its Protein A products primarily through value-added resellers, as well as through distributors internationally. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Alexander Rich M.D., 84
Co-Founder, Chairman, Chairman of Nominating & Corp. Governance Committee, Chairman of Compensation Committee, Member of Audit Committee and Member of Science & Technology Committee |
$
47.00K | N/A | Dr. Walter C. Herlihy Ph.D., 57
Chief Exec. Officer, Pres, Director and Member of Science & Technology Committee |
$
514.00K |
$
0 | Mr. William J. Kelly CPA, 38
Chief Financial Officer and Principal Accounting Officer |
$
235.00K |
$
0 | Dr. Daniel P. Witt Ph.D., 62
VP of Operations |
$
250.00K |
$
16.00K | Dr. James R. Rusche Ph.D., 55
Sr. VP of R&D |
$
307.00K |
$
27.00K |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
